Metformin for Pulmonary Hypertension
(PH-HFpEF Trial)
Trial Summary
What is the purpose of this trial?
The main objective of this study is to determine the clinical efficacy of metformin versus placebo and the therapeutic response with regards to functional capacity and hemodynamics in PH-HFpEF.
Research Team
Michael Risbano, MD, MA
Principal Investigator
University of Pittsburgh
Marc A Simon, MD, MS
Principal Investigator
University of California, San Francisco
Eligibility Criteria
This trial is for adults with PH-HFpEF, a type of heart failure with high blood pressure in the lungs. Participants must have been diagnosed within the last 6 months and show at least three signs of metabolic syndrome. People under 18, those with uncontrolled hypertension or very low blood pressure, severe diabetes, recent major heart events, certain chronic diseases, or who are pregnant/breastfeeding cannot join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive metformin or placebo to assess efficacy on exercise hemodynamics and functional capacity
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Metformin
- Placebo oral capsule
Metformin is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Type 2 diabetes
- Type 2 diabetes
- Type 2 diabetes
- Type 2 diabetes
- Type 2 diabetes
- Type 2 diabetes
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor
National Institute on Aging (NIA)
Collaborator